Son, 11,475 patient aspirin prophylaxis PSM study: 24% lower mortality [p=0.52], 7% higher progression [p=0.8], and 11% more cases [p=0.21] https://c19p.org/son
copied to clipboard
Effect of aspirin on coronavirus disease 2019
et al., Medicine, doi:10.1097/MD.0000000000026670
PSM retrospective case control study in South Korea, showing a trend towards lower mortality, but no significant differences with aspirin use.
|
risk of death, 24.0% lower, OR 0.76, p = 0.52, treatment 37 of 128 (28.9%) cases,
31 of 128 (24.2%) controls, case control OR, group 1, model 2 (most data in group and adjustments).
|
|
risk of progression, 7.0% higher, OR 1.07, p = 0.80, treatment 77 of 339 (22.7%) cases,
58 of 339 (17.1%) controls, case control OR, complications, group 1, model 2 (most data in group and adjustments).
|
|
risk of case, 11.0% higher, OR 1.11, p = 0.21, treatment 313 of 3,825 (8.2%) cases,
617 of 7,650 (8.1%) controls, case control OR, group 1, PSM 1, model 2 (most data in group and adjustments).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Son et al., 7/30/2021, retrospective, propensity score matching, South Korea, Asia, peer-reviewed, 6 authors.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.